By AuntMinnie.com staff writers

September 11, 2019 -- Bracco molecular imaging subsidiary Blue Earth Diagnostics is directing attention to several presentations at the upcoming annual meeting of the American Society for Radiation Oncology (ASTRO) later this week in Chicago.

Several studies at ASTRO 2019 will feature clinical experience with the company's Axumin (fluciclovine F-18) PET radiopharmaceutical, including a talk that will provide full results from the Fluciclovine (F-18) PET/CT in Biochemical Recurrence of Prostate Cancer (FALCON) trial.

In addition, researchers from the Technical University of Munich in Germany will report their initial clinical experience with using Blue Earth's "radiohybrid" prostate-specific membrane antigen (F-18 rhPSMA-7) imaging agent, the company said.


Copyright © 2019 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: